HMGB1, a biomarker and therapeutic target in COVID-19

COVID-19 is a respiratory disease caused by SARS-CoV-2 coronavirus. Although COVID-19 vaccines are authorized for the prevention of coronavirus disease, no existing vaccine is effective against all new viral variants. It is critical to have an effective therapeutic strategies for COVID-19.

HMGB1 is a multifunctional protein with various roles in different cellular compartments. Extracellular HMGB1, a key damage-associated molecular pattern (DAMP) molecule, is the central mediator of lethal inflammation in tissue damage or infection. HMGB1 is an increasingly attractive target in various human diseases including COVID-19.

HMGB1, a biomarker for severe COVID-19

HMGB1 promotes release of pro-inflammatory cytokines including TNF, IL-1 and IL-6. Chen et al. reported that elevated serum HMGB1 was associated with high mortality and lung cytokine storm in COVID-19 patients. Their results suggest HMGB1 is a biomarker for severe COVID-19. arigo offer comprehensive HMGB1 ELISA kits and more cytokine ELISA kits to accelerate the identification of prognostic markers in COVID-19. (Read more about HMGB1)

▶ Comprehensive HMGB1 ELISA Kits

Human HMGB1 ELISA Kit (ARG81185)
Mouse/Rat HMGB1 ELISA Kit (ARG81310)
Serum HMGB1 ELISA Kit (ARG81351)

Good for plasma, serum, cell culture supernatant, and cell/tissue lysate
HMGB1-specific
Easy and fast process
Multiple citations

▶ ELISA kits for COVID-19 biomarker candidates

Human Inflammatory Cytokine multiplex ELISA Kit (ARG80929)

A kit for detecting 8 inflammatory cytokines, including IL-1 alpha, IL-1 beta, IL-6, IL-8, GM-CSF, MCP-1, TNF alpha, and IFN gamma.

Human S100A8/A9 ELISA Kit (ARG82070)
Human IFN lambda ELISA Kit (ARG80169)
Pro-Inflammatory Cytokine ELISA Kits

HMGB1, a therapeutic target in COVID-19

HMGB1 contributes to lung cytokine storm and is considered as a potential target for the treatment of COVID-19. Recently, Chen et al. and Wei et al. reported a novel role of HMGB1 in ACE2 expression and viral entry. Chen et al. found that HMGB1 induces the expression of SARS-CoV-2 entry receptor ACE2 in lung epithelial cells. This result indicates that targeting HMGB1 shows benefits of preventing both cytokine storm and viral entry. arigo offers effective HMGB1 neutralizing antibody and more antibodies against potential therapeutic candidates to facilitate the research of therapeutic strategies in COVID-19.

HMGB1 Neutralizing antibody [SQab20175] (low endotoxin) (ARG66714)

You may be interested in…